293 related articles for article (PubMed ID: 23937415)
1. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Klempner SJ; Myers AP; Mills GB; Westin SN
Expert Opin Pharmacother; 2013 Nov; 14(16):2171-82. PubMed ID: 23937415
[TBL] [Abstract][Full Text] [Related]
2. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
4. Emerging growth factor receptor antagonists for ovarian cancer treatment.
Bonilla L; Oza A; Lheureux S
Expert Opin Emerg Drugs; 2018 Mar; 23(1):1-16. PubMed ID: 29528256
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
9. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
10. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA; Maoz A; Casabar JK; Machida H; Mabuchi S; Matsuo K
Expert Opin Investig Drugs; 2016 Jul; 25(7):781-96. PubMed ID: 27101098
[TBL] [Abstract][Full Text] [Related]
12. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
13. Targeting tyrosine-kinases in ovarian cancer.
Morotti M; Becker CM; Menada MV; Ferrero S
Expert Opin Investig Drugs; 2013 Oct; 22(10):1265-79. PubMed ID: 23815710
[TBL] [Abstract][Full Text] [Related]
14. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
Khosravi-Shahi P; Cabezon-Gutierrez L
Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Barra F; Laganà AS; Ghezzi F; Casarin J; Ferrero S
Gynecol Obstet Invest; 2019; 84(2):107-117. PubMed ID: 30304728
[TBL] [Abstract][Full Text] [Related]
18. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
Lawal AO; Musekiwa A; Grobler L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
[TBL] [Abstract][Full Text] [Related]
19. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
